retatrutide clinical development FDA Approval Status 2026: Everything We Know So Far Retatrutide: What We Know About

GLP-1 medications can help manage type 2 diabetes and obesity, but they may cause short-term mild-to-moderate side effects such as nausea, vomiting, diarrhoea, constipation, bloating, and decreased appetite, particularly at the beginning of treatment

The discussion highlights overlooked contributors such as brain inflammation, low brain derived neurotrophic factor, and metabolic dysfunction, while previewing emerging treatments including transcranial magnetic stimulation, ketamine, psychedelic assisted therapy, and lifestyle and metabolic interventions

GLP-1(32-36)amide pentapeptide increases basal energy expenditure and inhibits weight gain in obese mice

ALT, alanine aminotransferase

The biology of glucagon and the consequences of hyperglucagonemia

Feb 2, 2026 You are wasting peptides